A potential therapeutic role in multiple sclerosis for stigmast-5,22-dien-3 beta-ol myristate isolated from Capparis ovata

Acar O. O., GAZİOĞLU I., Kolak U., Sen A., TOPÇU G.

EUROBIOTECH JOURNAL, vol.1, no.3, pp.241-246, 2017 (ESCI) identifier

  • Publication Type: Article / Article
  • Volume: 1 Issue: 3
  • Publication Date: 2017
  • Doi Number: 10.24190/issn2564-615x/2017/03.08
  • Journal Indexes: Emerging Sources Citation Index (ESCI)
  • Page Numbers: pp.241-246
  • Bezmialem Vakıf University Affiliated: Yes


Multiple sclerosis (MS) is an autoimmune disease of the human central nervous system. It is one of the most common neurological disorders around the world and there is still no complete cure for MS. Purification of a terpenoid from Capparis ovata was carried out and its structure was elucidated as stigmast-5,22-dien-3 beta-ol, myristate (3 beta, 22E-stigmasteryl myristate; SDM) by NMR and mass spectral analyses. No information regarding its any health effect is available in the literature. In the present study, we have described its effects on inflammatory factors such as the expression levels of cytokines, chemokines and adhesion molecules as well as apoptosis/infiltration and myelination in SH-SY5Y cells. The expression levels of proinflammatory or inflammatory cytokines and chemokines such as NF-.B1, CCL5, CXCL9, CXCL10 and HIF1A along with T-cell activating cytokines such as IL-6 and TGFB1 were significantly downregulated with SDM treatment. Moreover, the expression levels of the main myelin proteins such as MBP, MAG and PLP that are essential for healthy myelin architecture were significantly up-regulated. The results presented in this study strongly suggest that the SDM offers a unique possibility to be used with autoimmune diseases, including MS due to its activity on the manipulation of cytokines and the promotion of myelin formation.